Validity of claims‐based definitions of left ventricular systolic dysfunction in Medicare patients
暂无分享,去创建一个
Jun Liu | Soko Setoguchi | N. Dreyer | R. Glynn | H. Mogun | S. Setoguchi | Jun S. Liu | Helen Mogun | Qian Li | Robert J. Glynn | Nancy A. Dreyer | Qian Li
[1] Fibrillation atriale et insuffisance cardiaque : une redoutable association de malfaiteurs , 2009 .
[2] Karl Swedberg,et al. Influence of Ejection Fraction on Cardiovascular Outcomes in a Broad Spectrum of Heart Failure Patients , 2005, Circulation.
[3] Hude Quan,et al. Administrative data have high variation in validity for recording heart failure. , 2010, The Canadian journal of cardiology.
[4] Perry M. Elliott,et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012 , 2010, European journal of heart failure.
[5] D A Savitz,et al. Estimating and correcting for confounder misclassification. , 1989, American journal of epidemiology.
[6] K. Swedberg,et al. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). , 1988, The American journal of cardiology.
[7] Adrian F Hernandez,et al. Linking inpatient clinical registry data to Medicare claims data using indirect identifiers. , 2009, American heart journal.
[8] A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. , 2001 .
[9] J. Avorn,et al. Tumor necrosis factor-alpha antagonist use and heart failure in elderly patients with rheumatoid arthritis. , 2008, American heart journal.
[10] S. Schneeweiss. Sensitivity analysis and external adjustment for unmeasured confounders in epidemiologic database studies of therapeutics , 2006, Pharmacoepidemiology and drug safety.
[11] K. Schulman,et al. Sex differences in the use of implantable cardioverter-defibrillators for primary and secondary prevention of sudden cardiac death. , 2007, JAMA.
[12] R. Harrison,et al. Guideline for the management of heart failure caused by systolic dysfunction: part II. Treatment. , 2001, American family physician.
[13] N. Dreyer,et al. Challenges in Comparing Effectiveness of Angiotensin Receptor Blockers vs. Angiotensin-Converting Enzyme Inhibitors for Hypertension in Medicare Data , 2011, Clinical pharmacology and therapeutics.
[14] Peter C Austin,et al. Effect of cardiac and noncardiac conditions on survival after defibrillator implantation. , 2007, Journal of the American College of Cardiology.
[15] Salim Yusuf,et al. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. , 1991, The New England journal of medicine.
[16] A. Tsiatis,et al. Cost-Effectiveness of Defibrillator Therapy or Amiodarone in Chronic Stable Heart Failure: Results From the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) , 2006, Circulation.
[17] B. Pitt,et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. , 1999, The New England journal of medicine.
[18] E. J. Brown,et al. The effect of digoxin on mortality and morbidity in patients with heart failure. , 1997, The New England journal of medicine.
[19] Long-term trends of angiotensin-converting enzyme inhibitor and angiotensin-receptor blocker use after heart failure hospitalization in community-dwelling seniors. , 2008, International journal of cardiology.
[20] B. Pitt,et al. Eplerenone , a Selective Aldosterone Blocker , in Patients with Left Ventricular Dysfunction after Myocardial Infarction , 2003 .
[21] Fach,et al. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in-Congestive Heart Failure (MERIT-HF) , 1999, The Lancet.
[22] J. Oss,et al. PROPHYLACTIC IMPLANTATION OF A DEFIBRILLATOR IN PATIENTS WITH MYOCARDIAL INFARCTION AND REDUCED EJECTION FRACTION , 2002 .
[23] N. Dreyer,et al. Challenges in Comparing Effectiveness of Angiotensin Receptor Blockers vs. Angiotensin-Converting Enzyme Inhibitors for Hypertension in Medicare Data , 2011, Clinical pharmacology and therapeutics.
[24] Peter C Austin,et al. Outcome of heart failure with preserved ejection fraction in a population-based study. , 2006, The New England journal of medicine.
[25] R. Gliklich,et al. Get with the guidelines for cardiovascular secondary prevention: pilot results. , 2004, Archives of internal medicine.
[26] K. Swedberg,et al. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. , 2007, JAMA.
[27] F. Tristani,et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. , 1991, The New England journal of medicine.
[28] Michael Böhm,et al. Kommentar zu den ESC-Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 , 2008, European journal of heart failure.
[29] Karl Swedberg,et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial , 2003, The Lancet.
[30] J. Avorn,et al. Improvements in long-term mortality after myocardial infarction and increased use of cardiovascular drugs after discharge: a 10-year trend analysis. , 2008, Journal of the American College of Cardiology.
[31] J. Avorn,et al. A review of uses of health care utilization databases for epidemiologic research on therapeutics. , 2005, Journal of clinical epidemiology.
[32] D. DeMets,et al. Effect of carvedilol on survival in severe chronic heart failure. , 2001, The New England journal of medicine.
[33] K. Bailey,et al. Clinical criteria and biochemical markers for the detection of systolic dysfunction. , 2000, Journal of cardiac failure.